Finance

Lists
002019:SHE
Yifan Pharmaceutical Co Ltd
CNÂ¥9.53
+1.28%
(+0.12) 1D
Nov 4, 3:04:12 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002019...
Open
CNÂ¥9.40
High
CNÂ¥9.59
Low
CNÂ¥9.37
Mkt. cap
11.45B
Avg. vol.
7.48M
Volume
12.05M
Dividend
1.05%
Quarterly dividend
CNÂ¥0.03
Ex-dividend date
May 29, 2026
P/E ratio
37.28
52-wk high
CNÂ¥14.73
52-wk low
CNÂ¥8.99
EPS
CNÂ¥0.26
Shares outstanding
1.22B
No. of employees
4K
Open
CNÂ¥9.40
High
CNÂ¥9.59
Low
CNÂ¥9.37
Mkt. cap
11.45B
Avg. vol.
7.48M
Volume
12.05M
Dividend
1.05%
Quarterly dividend
CNÂ¥0.03
Ex-dividend date
May 29, 2026
P/E ratio
37.28
52-wk high
CNÂ¥14.73
52-wk low
CNÂ¥8.99
EPS
CNÂ¥0.26
Shares outstanding
1.22B
No. of employees
4K
News stories
From web sources and news partners
About Yifan Pharmaceutical Co Ltd
CEO-
Employees4.18K
Founded1994
Headquarters-
SectorPharmaceutical industry
Industry-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.21B
1.26B
1.21B
1.25B
Cost of goods sold
709.78M
680.09M
660.52M
652.26M
Cost of revenue
709.78M
680.09M
660.52M
652.26M
Research and development expenses
99.51M
54.37M
84.82M
74.61M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
380.61M
352.15M
322.47M
381.80M
Operating expense
557.61M
426.93M
417.72M
471.97M
Total operating expenses
1.27B
1.11B
1.08B
1.12B
Operating income
-57.15M
148.49M
133.82M
129.73M
Other non operating income
-9.75M
-9.25M
3.87M
-23.87M
EBT including unusual items
-11.11M
120.86M
108.42M
104.65M
EBT excluding unusual items
-75.15M
130.13M
108.62M
112.73M
Income tax expense
-24.31M
25.15M
16.74M
32.24M
Effective tax rate
218.84%
20.81%
15.44%
30.81%
Other operating expenses
83.25M
11.12M
9.35M
14.30M
Net income
14.23M
106.83M
98.20M
91.95M
Net profit margin
1.18%
8.51%
8.10%
7.33%
Earnings per share
-
-
-
-
Interest and investment income
4.17M
2.64M
2.83M
2.20M
Interest expense
-10.67M
-11.75M
-11.28M
-15.94M
Net interest expenses
-6.51M
-9.11M
-8.46M
-13.74M
Depreciation and amortization charges
-
-
-
-
EBITDA
25.45M
231.09M
220.93M
212.32M
Gain or loss from assets sale
-12.70M
-
1.53M
-1.53M
Upcoming events
AI content may include mistakes. Learn more
Google apps